数据表明一种联合用药的热敏脂质体制剂在乳腺癌临床前模型中的抗肿瘤疗效。
Data demonstrating the anti-tumor efficacy of thermosensitive liposome formulations of a drug combination in pre-clinical models of breast cancer.
作者信息
Wang Xuehan, Regenold Maximilian, Dunne Michael, Bannigan Pauric, Allen Christine
机构信息
Leslie Dan Faculty of Pharmacy, University of Toronto, 144 College Street, Toronto, Ontario, M5S 3M2, Canada.
出版信息
Data Brief. 2023 Sep 9;50:109545. doi: 10.1016/j.dib.2023.109545. eCollection 2023 Oct.
Thermosensitive liposomes in combination with localized mild hyperthermia can improve the delivery of drug to solid tumor sites. For this reason, thermosensitive liposome formulations of a range of chemotherapy drugs have been designed. Our group previously developed and characterized a thermosensitive liposome formulation of the heat shock protein 90 inhibitor alvespimycin as a companion therapeutic to a thermosensitive liposome formulation equivalent in composition to ThermoDox (i.e., ThermoDXR), with the goal of increasing the therapeutic index of doxorubicin as the combination was revealed to be highly synergistic in a panel of human breast cancer cell lines including MDA-MB-231 (Dunne et al., 2019). The data presented here further describes the effect of the doxorubicin (DXR) and alvespimycin (ALV) combination and . Specifically, the combination effect in mouse breast cancer 4T1 cells and the efficacy of this heat-activated chemotherapy combination in both immunocompromised (MDA-MB-231 tumor bearing female SCID mice) and immunocompetent (4T1 tumor bearing female BALB/c mice) models of breast cancer.
热敏脂质体与局部轻度热疗相结合可改善药物向实体瘤部位的递送。因此，已经设计了一系列化疗药物的热敏脂质体制剂。我们小组之前开发并表征了热休克蛋白90抑制剂阿维司比星的热敏脂质体制剂，作为与成分等同于ThermoDox（即ThermoDXR）的热敏脂质体制剂的联合治疗药物，目的是提高阿霉素的治疗指数，因为该组合在包括MDA-MB-231在内的一组人乳腺癌细胞系中显示出高度协同作用（邓恩等人，2019年）。此处呈现的数据进一步描述了阿霉素（DXR）和阿维司比星（ALV）组合的效果。具体而言，是在小鼠乳腺癌4T1细胞中的联合效应以及这种热激活化疗组合在免疫受损（携带MDA-MB-231肿瘤的雌性SCID小鼠）和免疫健全（携带4T1肿瘤的雌性BALB/c小鼠）乳腺癌模型中的疗效。
Zotero 插件